MendAGene LLC's unique in-house patent-pending technologies produce gene therapy designs in a snap. Our favored approach to gene therapeutics is different than gene editing, because of perceived concerns about off-target risks of gene editing. Our designs improve the chance of success and are capable of reducing costs of development and approval.

In our design process, we use natural history data, identify a specific molecular abnormality, and target the underlying or proximate biological alteration. As a platform for designing gene therapeutics, we have designed for a wide variety of genetic conditions to help reduce, mute, slow, treat, or prevent types of Parkinsons, Sickle Cell, Polycystic Kidney Diseases, cancer, and more. If you or your organization have interest in bringing better therapeutics to market, email us at designs@MendAGene.com

Current opportunities for licensing and collaboration include designs to help mitigate the following genetic conditions: